Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVM-1118 ER in advanced cancers
NCT04336124Phase 1Completed
- Sponsor
- TaiRx, Inc.
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib in cancer, sponsored by TaiRx, Inc. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started May 2020; status: completed.
02
Drugs
dasatinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04336124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336124.